NR4A1 and breast carcinoma: mTORIs have been approved in the therapy of renal cancers; mantle cell lymphomas; advanced breast cancers (hormone receptor–positive); pancreatic, gastrointestinal, and pulmonary neuroendocrine cancers; and sporadic lymphangioleiomyomatosis.